FairJourney Biologics
FairJourney provides essential antibody discovery, engineering, and production services for small and mid-sized biopharma companies, facilitating their drug discovery process.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | €900m Valuation: €900m 16.8x EV/Revenue | Buyout | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 44 % | 19 % | 36 % | 27 % | 48 % | 62 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 57 % | 50 % | 58 % | 51 % | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 49 % | 39 % | 43 % | 36 % | 29 % | 37 % | 37 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
FairJourney Biologics is a leading provider of high-quality antibody engineering services, specializing in the discovery and development of therapeutic antibodies. The company operates in the biotechnology sector, serving pharmaceutical companies, research institutions, and diagnostic firms. FairJourney Biologics employs advanced techniques such as phage display to discover antibodies from rodent immune repertoires, which are then humanized through affinity-driven selections to maintain potency. The business model revolves around offering end-to-end solutions, from initial discovery to final development, ensuring optimal specificity and sensitivity for diagnostic assays. Revenue is generated through project-based contracts and long-term partnerships with clients seeking innovative antibody solutions.
Keywords: antibody engineering, phage display, therapeutic antibodies, biotechnology, diagnostic assays, humanization, affinity selection, pharmaceutical, research institutions, diagnostic firms.
Tech stack
Investments by FairJourney Biologics
Edit